nodes	percent_of_prediction	percent_of_DWPC	metapath
Norepinephrine—L-DOPA—Melphalan—ovarian cancer	0.527	1	CrCrCtD
Norepinephrine—SLC22A3—Melphalan—ovarian cancer	0.32	1	CbGbCtD
Norepinephrine—Extravasation—Carboplatin—ovarian cancer	0.00287	0.104	CcSEcCtD
Norepinephrine—SLC18A1—vagina—ovarian cancer	0.00283	0.062	CbGeAlD
Norepinephrine—Isoprenaline—MAPK1—ovarian cancer	0.00198	1	CrCbGaD
Norepinephrine—SLC18A1—lymph node—ovarian cancer	0.00183	0.0401	CbGeAlD
Norepinephrine—ADRB3—female reproductive system—ovarian cancer	0.00175	0.0384	CbGeAlD
Norepinephrine—ADRB3—female gonad—ovarian cancer	0.0016	0.035	CbGeAlD
Norepinephrine—Lactic acidosis—Epirubicin—ovarian cancer	0.00154	0.0559	CcSEcCtD
Norepinephrine—Lactic acidosis—Doxorubicin—ovarian cancer	0.00143	0.0517	CcSEcCtD
Norepinephrine—SLC18A2—uterine cervix—ovarian cancer	0.00133	0.0292	CbGeAlD
Norepinephrine—ADRA1D—epithelium—ovarian cancer	0.00133	0.0291	CbGeAlD
Norepinephrine—Extravasation—Topotecan—ovarian cancer	0.00131	0.0476	CcSEcCtD
Norepinephrine—Extravasation—Melphalan—ovarian cancer	0.00129	0.0466	CcSEcCtD
Norepinephrine—SLC22A3—myometrium—ovarian cancer	0.00122	0.0267	CbGeAlD
Norepinephrine—SLC18A2—endometrium—ovarian cancer	0.00121	0.0264	CbGeAlD
Norepinephrine—SLC22A3—embryo—ovarian cancer	0.00117	0.0257	CbGeAlD
Norepinephrine—Extravasation—Vinorelbine—ovarian cancer	0.00112	0.0407	CcSEcCtD
Norepinephrine—SLC18A2—uterus—ovarian cancer	0.00111	0.0244	CbGeAlD
Norepinephrine—SLC18A2—female reproductive system—ovarian cancer	0.000999	0.0219	CbGeAlD
Norepinephrine—ADRA1D—female reproductive system—ovarian cancer	0.000987	0.0216	CbGeAlD
Norepinephrine—SLC22A3—uterine cervix—ovarian cancer	0.00095	0.0208	CbGeAlD
Norepinephrine—Retrosternal pain—Epirubicin—ovarian cancer	0.000936	0.0339	CcSEcCtD
Norepinephrine—ADRA2C—myometrium—ovarian cancer	0.000926	0.0203	CbGeAlD
Norepinephrine—SLC18A2—vagina—ovarian cancer	0.000904	0.0198	CbGeAlD
Norepinephrine—SLC22A5—myometrium—ovarian cancer	0.000887	0.0194	CbGeAlD
Norepinephrine—Retrosternal pain—Doxorubicin—ovarian cancer	0.000866	0.0314	CcSEcCtD
Norepinephrine—SLC22A3—endometrium—ovarian cancer	0.000859	0.0188	CbGeAlD
Norepinephrine—Vomiting—Altretamine—ovarian cancer	0.000821	0.0298	CcSEcCtD
Norepinephrine—SLC18A2—testis—ovarian cancer	0.000806	0.0177	CbGeAlD
Norepinephrine—SLC22A3—gonad—ovarian cancer	0.000797	0.0175	CbGeAlD
Norepinephrine—SLC6A2—decidua—ovarian cancer	0.000775	0.017	CbGeAlD
Norepinephrine—ADRA1A—epithelium—ovarian cancer	0.000763	0.0167	CbGeAlD
Norepinephrine—Extravasation—Paclitaxel—ovarian cancer	0.000755	0.0274	CcSEcCtD
Norepinephrine—ADRA2A—myometrium—ovarian cancer	0.000739	0.0162	CbGeAlD
Norepinephrine—ADRA2C—uterine cervix—ovarian cancer	0.000721	0.0158	CbGeAlD
Norepinephrine—ADRB1—female reproductive system—ovarian cancer	0.000717	0.0157	CbGeAlD
Norepinephrine—SLC22A3—female reproductive system—ovarian cancer	0.000711	0.0156	CbGeAlD
Norepinephrine—SLC22A5—uterine cervix—ovarian cancer	0.00069	0.0151	CbGeAlD
Norepinephrine—ADRA2C—decidua—ovarian cancer	0.000687	0.0151	CbGeAlD
Norepinephrine—SLC6A2—gonad—ovarian cancer	0.000683	0.015	CbGeAlD
Norepinephrine—SLC22A1—vagina—ovarian cancer	0.000673	0.0148	CbGeAlD
Norepinephrine—Blood pressure increased—Paclitaxel—ovarian cancer	0.000659	0.0239	CcSEcCtD
Norepinephrine—ADRA2C—endometrium—ovarian cancer	0.000652	0.0143	CbGeAlD
Norepinephrine—SLC22A3—female gonad—ovarian cancer	0.000647	0.0142	CbGeAlD
Norepinephrine—SLC22A3—vagina—ovarian cancer	0.000643	0.0141	CbGeAlD
Norepinephrine—Extravasation—Docetaxel—ovarian cancer	0.00064	0.0232	CcSEcCtD
Norepinephrine—SLC22A5—endometrium—ovarian cancer	0.000624	0.0137	CbGeAlD
Norepinephrine—Sweating—Topotecan—ovarian cancer	0.000614	0.0223	CcSEcCtD
Norepinephrine—SLC6A2—female reproductive system—ovarian cancer	0.00061	0.0134	CbGeAlD
Norepinephrine—ADRA2C—uterus—ovarian cancer	0.000601	0.0132	CbGeAlD
Norepinephrine—SLC18A2—lymph node—ovarian cancer	0.000584	0.0128	CbGeAlD
Norepinephrine—ADRA2A—uterine cervix—ovarian cancer	0.000575	0.0126	CbGeAlD
Norepinephrine—SLC22A3—testis—ovarian cancer	0.000574	0.0126	CbGeAlD
Norepinephrine—Blood pressure increased—Docetaxel—ovarian cancer	0.000559	0.0202	CcSEcCtD
Norepinephrine—ADRA2A—decidua—ovarian cancer	0.000548	0.012	CbGeAlD
Norepinephrine—ADRA2A—endometrium—ovarian cancer	0.00052	0.0114	CbGeAlD
Norepinephrine—SLC22A5—female reproductive system—ovarian cancer	0.000517	0.0113	CbGeAlD
Norepinephrine—Arrhythmia—Melphalan—ovarian cancer	0.000503	0.0182	CcSEcCtD
Norepinephrine—SLC6A2—testis—ovarian cancer	0.000492	0.0108	CbGeAlD
Norepinephrine—ADRA2C—female gonad—ovarian cancer	0.000491	0.0108	CbGeAlD
Norepinephrine—ADRA2C—vagina—ovarian cancer	0.000488	0.0107	CbGeAlD
Norepinephrine—ADRA2A—gonad—ovarian cancer	0.000483	0.0106	CbGeAlD
Norepinephrine—ADRA2A—uterus—ovarian cancer	0.000479	0.0105	CbGeAlD
Norepinephrine—SLC22A5—female gonad—ovarian cancer	0.000471	0.0103	CbGeAlD
Norepinephrine—SLC22A5—vagina—ovarian cancer	0.000468	0.0103	CbGeAlD
Norepinephrine—DRD2—testis—ovarian cancer	0.000448	0.00983	CbGeAlD
Norepinephrine—Arrhythmia—Vinorelbine—ovarian cancer	0.00044	0.0159	CcSEcCtD
Norepinephrine—ADRA2C—testis—ovarian cancer	0.000436	0.00955	CbGeAlD
Norepinephrine—Extravasation—Epirubicin—ovarian cancer	0.000432	0.0156	CcSEcCtD
Norepinephrine—ADRA2A—female reproductive system—ovarian cancer	0.000431	0.00945	CbGeAlD
Norepinephrine—Chest pain—Topotecan—ovarian cancer	0.000426	0.0154	CcSEcCtD
Norepinephrine—SLC22A5—testis—ovarian cancer	0.000417	0.00915	CbGeAlD
Norepinephrine—Chest pain—Melphalan—ovarian cancer	0.000417	0.0151	CcSEcCtD
Norepinephrine—SLC22A3—lymph node—ovarian cancer	0.000416	0.00912	CbGeAlD
Norepinephrine—Extravasation—Doxorubicin—ovarian cancer	0.0004	0.0145	CcSEcCtD
Norepinephrine—Hyperhidrosis—Topotecan—ovarian cancer	0.000395	0.0143	CcSEcCtD
Norepinephrine—ADRA2A—female gonad—ovarian cancer	0.000392	0.00859	CbGeAlD
Norepinephrine—ADRA2A—vagina—ovarian cancer	0.00039	0.00854	CbGeAlD
Norepinephrine—Hypertension—Vinorelbine—ovarian cancer	0.00037	0.0134	CcSEcCtD
Norepinephrine—Chest pain—Vinorelbine—ovarian cancer	0.000365	0.0132	CcSEcCtD
Norepinephrine—Dyspnoea—Topotecan—ovarian cancer	0.000364	0.0132	CcSEcCtD
Norepinephrine—Dyspnoea—Melphalan—ovarian cancer	0.000357	0.0129	CcSEcCtD
Norepinephrine—SLC6A2—lymph node—ovarian cancer	0.000357	0.00782	CbGeAlD
Norepinephrine—ADRA2A—testis—ovarian cancer	0.000348	0.00762	CbGeAlD
Norepinephrine—Bradycardia—Paclitaxel—ovarian cancer	0.000337	0.0122	CcSEcCtD
Norepinephrine—ADRA2C—lymph node—ovarian cancer	0.000316	0.00692	CbGeAlD
Norepinephrine—Dyspnoea—Vinorelbine—ovarian cancer	0.000312	0.0113	CcSEcCtD
Norepinephrine—SLC22A5—lymph node—ovarian cancer	0.000303	0.00663	CbGeAlD
Norepinephrine—Arrhythmia—Paclitaxel—ovarian cancer	0.000296	0.0107	CcSEcCtD
Norepinephrine—Vomiting—Chlorambucil—ovarian cancer	0.000292	0.0106	CcSEcCtD
Norepinephrine—Vomiting—Topotecan—ovarian cancer	0.00026	0.00941	CcSEcCtD
Norepinephrine—Headache—Topotecan—ovarian cancer	0.000256	0.00928	CcSEcCtD
Norepinephrine—Vomiting—Melphalan—ovarian cancer	0.000254	0.00922	CcSEcCtD
Norepinephrine—ADRA2A—lymph node—ovarian cancer	0.000252	0.00553	CbGeAlD
Norepinephrine—Arrhythmia—Docetaxel—ovarian cancer	0.000251	0.00908	CcSEcCtD
Norepinephrine—Hypertension—Paclitaxel—ovarian cancer	0.000249	0.00901	CcSEcCtD
Norepinephrine—Chest pain—Paclitaxel—ovarian cancer	0.000245	0.00889	CcSEcCtD
Norepinephrine—Anxiety—Paclitaxel—ovarian cancer	0.000244	0.00886	CcSEcCtD
Norepinephrine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000227	0.00824	CcSEcCtD
Norepinephrine—Vomiting—Vinorelbine—ovarian cancer	0.000222	0.00805	CcSEcCtD
Norepinephrine—Headache—Vinorelbine—ovarian cancer	0.000219	0.00794	CcSEcCtD
Norepinephrine—Hypertension—Docetaxel—ovarian cancer	0.000211	0.00764	CcSEcCtD
Norepinephrine—Dyspnoea—Paclitaxel—ovarian cancer	0.00021	0.0076	CcSEcCtD
Norepinephrine—Chest pain—Docetaxel—ovarian cancer	0.000208	0.00753	CcSEcCtD
Norepinephrine—Sweating—Epirubicin—ovarian cancer	0.000202	0.00732	CcSEcCtD
Norepinephrine—Bradycardia—Epirubicin—ovarian cancer	0.000193	0.00698	CcSEcCtD
Norepinephrine—Sweating—Doxorubicin—ovarian cancer	0.000187	0.00677	CcSEcCtD
Norepinephrine—Bradycardia—Doxorubicin—ovarian cancer	0.000178	0.00646	CcSEcCtD
Norepinephrine—Dyspnoea—Docetaxel—ovarian cancer	0.000178	0.00644	CcSEcCtD
Norepinephrine—Arrhythmia—Epirubicin—ovarian cancer	0.000169	0.00612	CcSEcCtD
Norepinephrine—Arrhythmia—Doxorubicin—ovarian cancer	0.000156	0.00567	CcSEcCtD
Norepinephrine—Vomiting—Paclitaxel—ovarian cancer	0.00015	0.00542	CcSEcCtD
Norepinephrine—Headache—Paclitaxel—ovarian cancer	0.000147	0.00534	CcSEcCtD
Norepinephrine—Hypertension—Epirubicin—ovarian cancer	0.000142	0.00515	CcSEcCtD
Norepinephrine—Chest pain—Epirubicin—ovarian cancer	0.00014	0.00508	CcSEcCtD
Norepinephrine—Anxiety—Epirubicin—ovarian cancer	0.00014	0.00506	CcSEcCtD
Norepinephrine—Hypertension—Doxorubicin—ovarian cancer	0.000132	0.00477	CcSEcCtD
Norepinephrine—Hyperhidrosis—Epirubicin—ovarian cancer	0.00013	0.00471	CcSEcCtD
Norepinephrine—Chest pain—Doxorubicin—ovarian cancer	0.00013	0.0047	CcSEcCtD
Norepinephrine—Anxiety—Doxorubicin—ovarian cancer	0.000129	0.00469	CcSEcCtD
Norepinephrine—Vomiting—Docetaxel—ovarian cancer	0.000127	0.00459	CcSEcCtD
Norepinephrine—Headache—Docetaxel—ovarian cancer	0.000125	0.00452	CcSEcCtD
Norepinephrine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.00012	0.00436	CcSEcCtD
Norepinephrine—Dyspnoea—Epirubicin—ovarian cancer	0.00012	0.00434	CcSEcCtD
Norepinephrine—Dyspnoea—Doxorubicin—ovarian cancer	0.000111	0.00402	CcSEcCtD
Norepinephrine—Vomiting—Epirubicin—ovarian cancer	8.55e-05	0.0031	CcSEcCtD
Norepinephrine—Headache—Epirubicin—ovarian cancer	8.42e-05	0.00305	CcSEcCtD
Norepinephrine—Vomiting—Doxorubicin—ovarian cancer	7.91e-05	0.00287	CcSEcCtD
Norepinephrine—Headache—Doxorubicin—ovarian cancer	7.79e-05	0.00282	CcSEcCtD
Norepinephrine—ADRA1B—Signaling Pathways—ERBB2—ovarian cancer	5.97e-06	7.77e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—GPCR downstream signaling—AKT1—ovarian cancer	5.95e-06	7.75e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—CASP3—ovarian cancer	5.95e-06	7.75e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—GPCR downstream signaling—PIK3CA—ovarian cancer	5.95e-06	7.74e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—IL2—ovarian cancer	5.94e-06	7.73e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—CDKN1B—ovarian cancer	5.94e-06	7.73e-05	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—PTEN—ovarian cancer	5.93e-06	7.72e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling by GPCR—IL6—ovarian cancer	5.91e-06	7.7e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—CASP3—ovarian cancer	5.9e-06	7.68e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—MTOR—ovarian cancer	5.89e-06	7.67e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—PIK3CB—ovarian cancer	5.89e-06	7.67e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—IL2—ovarian cancer	5.89e-06	7.66e-05	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling Pathways—IL6—ovarian cancer	5.89e-06	7.66e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling by GPCR—KRAS—ovarian cancer	5.88e-06	7.65e-05	CbGpPWpGaD
Norepinephrine—ADRB2—GPCR downstream signaling—AKT1—ovarian cancer	5.88e-06	7.65e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling by GPCR—IL6—ovarian cancer	5.86e-06	7.63e-05	CbGpPWpGaD
Norepinephrine—SLC22A3—Metabolism—AKT1—ovarian cancer	5.85e-06	7.61e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—CASP3—ovarian cancer	5.82e-06	7.58e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—PIK3CB—ovarian cancer	5.82e-06	7.57e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—ABCB1—ovarian cancer	5.81e-06	7.57e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—IL2—ovarian cancer	5.81e-06	7.57e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—CCND1—ovarian cancer	5.79e-06	7.54e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—MAPK1—ovarian cancer	5.79e-06	7.53e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling by GPCR—IL6—ovarian cancer	5.78e-06	7.53e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—EGFR—ovarian cancer	5.78e-06	7.53e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—CXCL8—ovarian cancer	5.76e-06	7.49e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—CCND1—ovarian cancer	5.74e-06	7.47e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—CTNNB1—ovarian cancer	5.74e-06	7.47e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling by GPCR—HRAS—ovarian cancer	5.72e-06	7.44e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—TYMS—ovarian cancer	5.71e-06	7.43e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—CTNNB1—ovarian cancer	5.68e-06	7.4e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—CCND1—ovarian cancer	5.67e-06	7.38e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—CXCL8—ovarian cancer	5.66e-06	7.37e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling by GPCR—HRAS—ovarian cancer	5.63e-06	7.32e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—MMP9—ovarian cancer	5.62e-06	7.32e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—CDKN1B—ovarian cancer	5.62e-06	7.32e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—CTNNB1—ovarian cancer	5.61e-06	7.3e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling by GPCR—PIK3CA—ovarian cancer	5.61e-06	7.3e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—PTEN—ovarian cancer	5.59e-06	7.28e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—PIK3CD—ovarian cancer	5.58e-06	7.26e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—MMP9—ovarian cancer	5.57e-06	7.25e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—GPCR downstream signaling—AKT1—ovarian cancer	5.56e-06	7.24e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—VEGFA—ovarian cancer	5.54e-06	7.21e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—PTEN—ovarian cancer	5.54e-06	7.21e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—CDKN1B—ovarian cancer	5.53e-06	7.2e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—GPCR downstream signaling—PIK3CA—ovarian cancer	5.53e-06	7.19e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—CASP3—ovarian cancer	5.51e-06	7.17e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—ERBB2—ovarian cancer	5.51e-06	7.17e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—MMP9—ovarian cancer	5.5e-06	7.16e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—IL2—ovarian cancer	5.5e-06	7.16e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—STAT3—ovarian cancer	5.49e-06	7.14e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—NRAS—ovarian cancer	5.48e-06	7.13e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling by GPCR—IL6—ovarian cancer	5.47e-06	7.12e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—GPCR downstream signaling—AKT1—ovarian cancer	5.47e-06	7.12e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—PTEN—ovarian cancer	5.47e-06	7.12e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—KRAS—ovarian cancer	5.46e-06	7.11e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling by GPCR—AKT1—ovarian cancer	5.46e-06	7.1e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—PIK3CB—ovarian cancer	5.43e-06	7.07e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—MTOR—ovarian cancer	5.43e-06	7.07e-05	CbGpPWpGaD
Norepinephrine—ADRB3—Signaling Pathways—AKT1—ovarian cancer	5.43e-06	7.07e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—CASP3—ovarian cancer	5.42e-06	7.06e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—IL2—ovarian cancer	5.41e-06	7.05e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling by GPCR—AKT1—ovarian cancer	5.41e-06	7.03e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling by GPCR—PIK3CA—ovarian cancer	5.4e-06	7.03e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling by GPCR—IL6—ovarian cancer	5.39e-06	7.01e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—CCND1—ovarian cancer	5.36e-06	6.98e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling by GPCR—AKT1—ovarian cancer	5.34e-06	6.95e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—CTNNB1—ovarian cancer	5.31e-06	6.91e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—ERBB2—ovarian cancer	5.31e-06	6.91e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—CCND1—ovarian cancer	5.28e-06	6.87e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—MAPK3—ovarian cancer	5.24e-06	6.82e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—MTOR—ovarian cancer	5.24e-06	6.81e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—PIK3CB—ovarian cancer	5.24e-06	6.81e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—CTNNB1—ovarian cancer	5.23e-06	6.8e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—CXCL8—ovarian cancer	5.22e-06	6.8e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—MMP9—ovarian cancer	5.21e-06	6.78e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling by GPCR—HRAS—ovarian cancer	5.19e-06	6.75e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—PTEN—ovarian cancer	5.18e-06	6.74e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	5.12e-06	6.67e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	5.1e-06	6.64e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—MYC—ovarian cancer	5.1e-06	6.64e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	5.09e-06	6.63e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—VEGFA—ovarian cancer	5.05e-06	6.57e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling by GPCR—AKT1—ovarian cancer	5.05e-06	6.57e-05	CbGpPWpGaD
Norepinephrine—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	5.04e-06	6.57e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	5.03e-06	6.55e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—PTEN—ovarian cancer	5.03e-06	6.54e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	5.02e-06	6.53e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	5e-06	6.51e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—STAT3—ovarian cancer	5e-06	6.51e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	5e-06	6.51e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—CASP3—ovarian cancer	5e-06	6.51e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—IL2—ovarian cancer	4.99e-06	6.5e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—MAPK1—ovarian cancer	4.99e-06	6.49e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—NRAS—ovarian cancer	4.99e-06	6.49e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—EGFR—ovarian cancer	4.99e-06	6.49e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	4.97e-06	6.47e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling by GPCR—IL6—ovarian cancer	4.97e-06	6.46e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	4.96e-06	6.45e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	4.94e-06	6.43e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—VEGFA—ovarian cancer	4.94e-06	6.43e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	4.93e-06	6.42e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	4.91e-06	6.39e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—STAT3—ovarian cancer	4.89e-06	6.37e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—NRAS—ovarian cancer	4.88e-06	6.35e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—CCND1—ovarian cancer	4.87e-06	6.33e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	4.86e-06	6.33e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	4.86e-06	6.33e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	4.86e-06	6.33e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	4.82e-06	6.27e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	4.82e-06	6.27e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—IL2—ovarian cancer	4.81e-06	6.26e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	4.78e-06	6.23e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—MAPK3—ovarian cancer	4.78e-06	6.22e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	4.73e-06	6.16e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—MMP9—ovarian cancer	4.72e-06	6.15e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—KRAS—ovarian cancer	4.71e-06	6.13e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—PTEN—ovarian cancer	4.7e-06	6.11e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	4.69e-06	6.1e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	4.67e-06	6.08e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	4.67e-06	6.08e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—MAPK3—ovarian cancer	4.67e-06	6.08e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—MYC—ovarian cancer	4.65e-06	6.05e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	4.64e-06	6.04e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	4.64e-06	6.04e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	4.63e-06	6.02e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	4.62e-06	6.01e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—MYC—ovarian cancer	4.6e-06	5.99e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—CAV1—ovarian cancer	4.6e-06	5.99e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	4.6e-06	5.99e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling by GPCR—AKT1—ovarian cancer	4.58e-06	5.96e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	4.57e-06	5.94e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	4.56e-06	5.93e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	4.55e-06	5.92e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—MAPK1—ovarian cancer	4.55e-06	5.92e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—MYC—ovarian cancer	4.55e-06	5.92e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—EGFR—ovarian cancer	4.55e-06	5.92e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	4.54e-06	5.91e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	4.52e-06	5.89e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	4.52e-06	5.88e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	4.5e-06	5.86e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	4.5e-06	5.86e-05	CbGpPWpGaD
Norepinephrine—SLC22A2—Metabolism—PIK3CA—ovarian cancer	4.49e-06	5.84e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	4.47e-06	5.82e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—IL2—ovarian cancer	4.47e-06	5.81e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—MAPK1—ovarian cancer	4.45e-06	5.79e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—EGFR—ovarian cancer	4.45e-06	5.79e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	4.45e-06	5.79e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	4.42e-06	5.76e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	4.41e-06	5.74e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.4e-06	5.72e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Metabolism—PIK3CA—ovarian cancer	4.37e-06	5.68e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	4.36e-06	5.67e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	4.35e-06	5.66e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—PIK3CA—ovarian cancer	4.33e-06	5.63e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	4.31e-06	5.61e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—MYC—ovarian cancer	4.3e-06	5.6e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—KRAS—ovarian cancer	4.29e-06	5.59e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	4.25e-06	5.54e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—VEGFA—ovarian cancer	4.24e-06	5.52e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—MYC—ovarian cancer	4.23e-06	5.51e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	4.23e-06	5.5e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	4.21e-06	5.48e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	4.21e-06	5.48e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	4.2e-06	5.47e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—KRAS—ovarian cancer	4.2e-06	5.47e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—STAT3—ovarian cancer	4.2e-06	5.47e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—PIK3CG—ovarian cancer	4.19e-06	5.45e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—NRAS—ovarian cancer	4.19e-06	5.45e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—TP53—ovarian cancer	4.19e-06	5.45e-05	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—PIK3CA—ovarian cancer	4.18e-06	5.45e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	4.14e-06	5.39e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	4.14e-06	5.39e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	4.1e-06	5.34e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	4.09e-06	5.32e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	4.05e-06	5.27e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	4.04e-06	5.25e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—MAPK3—ovarian cancer	4.01e-06	5.22e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—HRAS—ovarian cancer	4.01e-06	5.21e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	3.97e-06	5.17e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—PIK3CA—ovarian cancer	3.94e-06	5.13e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	3.91e-06	5.09e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	3.91e-06	5.09e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—MYC—ovarian cancer	3.9e-06	5.08e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	3.87e-06	5.03e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—PIK3CA—ovarian cancer	3.86e-06	5.02e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—IL6—ovarian cancer	3.83e-06	4.99e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—MAPK1—ovarian cancer	3.82e-06	4.97e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—EGFR—ovarian cancer	3.82e-06	4.97e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—TP53—ovarian cancer	3.82e-06	4.97e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	3.8e-06	4.94e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—TP53—ovarian cancer	3.78e-06	4.92e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—MYC—ovarian cancer	3.76e-06	4.89e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	3.76e-06	4.89e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	3.75e-06	4.88e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—TP53—ovarian cancer	3.73e-06	4.86e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—PIK3CD—ovarian cancer	3.68e-06	4.8e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	3.68e-06	4.79e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	3.68e-06	4.79e-05	CbGpPWpGaD
Norepinephrine—SLC22A2—Metabolism—AKT1—ovarian cancer	3.67e-06	4.77e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	3.65e-06	4.75e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—HRAS—ovarian cancer	3.65e-06	4.75e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	3.62e-06	4.71e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—KRAS—ovarian cancer	3.61e-06	4.69e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	3.59e-06	4.68e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	3.59e-06	4.67e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—HRAS—ovarian cancer	3.57e-06	4.65e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Metabolism—AKT1—ovarian cancer	3.57e-06	4.64e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—PIK3CA—ovarian cancer	3.55e-06	4.62e-05	CbGpPWpGaD
Norepinephrine—ADRA1D—Signaling Pathways—AKT1—ovarian cancer	3.54e-06	4.6e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—TP53—ovarian cancer	3.53e-06	4.6e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—MYC—ovarian cancer	3.49e-06	4.55e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—IL6—ovarian cancer	3.49e-06	4.55e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—TP53—ovarian cancer	3.48e-06	4.52e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	3.47e-06	4.52e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—IL6—ovarian cancer	3.46e-06	4.5e-05	CbGpPWpGaD
Norepinephrine—SLC22A1—Metabolism—AKT1—ovarian cancer	3.42e-06	4.45e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	3.42e-06	4.45e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—IL6—ovarian cancer	3.42e-06	4.45e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	3.42e-06	4.45e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	3.38e-06	4.4e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	3.32e-06	4.33e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	3.31e-06	4.31e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—IL6—ovarian cancer	3.23e-06	4.21e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	3.23e-06	4.2e-05	CbGpPWpGaD
Norepinephrine—ADRB1—Signaling Pathways—AKT1—ovarian cancer	3.22e-06	4.19e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—PIK3CB—ovarian cancer	3.21e-06	4.18e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—TP53—ovarian cancer	3.2e-06	4.17e-05	CbGpPWpGaD
Norepinephrine—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	3.19e-06	4.16e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	3.19e-06	4.15e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—IL6—ovarian cancer	3.18e-06	4.14e-05	CbGpPWpGaD
Norepinephrine—ADRB2—Signaling Pathways—AKT1—ovarian cancer	3.15e-06	4.1e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—TP53—ovarian cancer	3.09e-06	4.02e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—HRAS—ovarian cancer	3.07e-06	3.99e-05	CbGpPWpGaD
Norepinephrine—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	2.98e-06	3.88e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	2.97e-06	3.86e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	2.95e-06	3.84e-05	CbGpPWpGaD
Norepinephrine—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	2.94e-06	3.82e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—IL6—ovarian cancer	2.93e-06	3.82e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Metabolism—AKT1—ovarian cancer	2.9e-06	3.77e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—TP53—ovarian cancer	2.87e-06	3.73e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—IL6—ovarian cancer	2.83e-06	3.68e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—PTEN—ovarian cancer	2.78e-06	3.61e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	2.74e-06	3.57e-05	CbGpPWpGaD
Norepinephrine—DRD2—Signaling Pathways—AKT1—ovarian cancer	2.71e-06	3.52e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—IL6—ovarian cancer	2.63e-06	3.42e-05	CbGpPWpGaD
Norepinephrine—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	2.61e-06	3.39e-05	CbGpPWpGaD
Norepinephrine—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	2.42e-06	3.15e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—PIK3CA—ovarian cancer	1.96e-06	2.55e-05	CbGpPWpGaD
Norepinephrine—CYP1A2—Metabolism—AKT1—ovarian cancer	1.6e-06	2.08e-05	CbGpPWpGaD
